GlassScriptPhysician profile
Era C Murzaku
NPI 1275927162
$5,660.50
in general payments reported to CMS, 2019-2025
30 companies · $896 in 2025
The $896 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $983 · 2020: $1,148 · 2021: $1,104 · 2022: $877 · 2023: $337 · 2024: $316 · 2025: $896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,549.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,561.49 | 2019-2025 | |
| Galderma Laboratories, L.P. | $546.23 | 2019-2025 | Nemluvio, Oracea, Aklief |
| Sun Pharmaceutical Industries INC. | $373.56 | 2019-2022 | |
| Leo Pharma INC. | $290.23 | 2019-2025 | Anzupgo, Adbry |
| Regeneron Healthcare Solutions, INC. | $288.17 | 2020-2025 | Dupixent |
| Lilly USA, LLC | $285.00 | 2019-2022 | |
| Almirall LLC | $254.22 | 2019-2025 | Seysara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $246.30 | 2019-2025 | Cabtreo |
| Novartis Pharmaceuticals Corporation | $205.74 | 2019-2025 | |
| Janssen Biotech, INC. | $200.68 | 2020-2025 | Tremfya |
| Amgen INC. | $200.57 | 2020-2025 | Otezla, Otezla |
| Ucb, INC. | $181.50 | 2020-2025 | Bimzelx |
| Incyte Corporation | $141.73 | 2021-2025 | Opzelura |
| Genzyme Corporation | $135.91 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $112.27 | 2019-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $100.11 | 2025 | Daxxify |
| Journey Medical Corporation | $95.64 | 2020-2025 | |
| Pfizer INC. | $81.28 | 2019-2025 | |
| Dermira, INC. | $69.18 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $63.81 | 2020-2021 | |
| Epi Health, LLC | $43.74 | 2020-2021 | |
| Arcutis Biotherapeutics, INC. | $32.45 | 2025 | Zoryve |
| Botanix Sb INC | $29.12 | 2025 | Sofdra |
| E.R. Squibb & Sons, L.L.C. | $27.31 | 2025 | Sotyktu |
| Celgene Corporation | $18.88 | 2019 | |
| Organon LLC | $18.81 | 2025 | |
| Krystal Biotech INC | $16.57 | 2025 | Vyjuvek |
| Nabriva Therapeutics, Plc | $15.47 | 2021 | |
| Sandoz INC. | $12.75 | 2020 | |
| Icad, INC | $11.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Era Murzaku listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.